Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on March 27, 2018, reporting an event that occurred on March 26, 2018. The registrant is a Delaware corporation headquartered in Boulder, Colorado, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance.
Material Changes
The material change reported is the initiation of a Phase 1 clinical trial for the product candidate MRG-110. This trial is being conducted by Les Laboratoires Servier and Institut de Recherches Servier (collectively, "Servier") under a License and Collaboration Agreement with Miragen. MRG-110 is an inhibitor of microRNA-92 intended for the treatment of heart failure and other ischemic diseases.
Outlook and Management Commentary
- Clinical Trial Details: The Phase 1 trial will evaluate the safety and tolerability of MRG-110 using a systemic dosing protocol.
- Enrollment Plan: The trial is planned to enroll 49 male subjects aged 18 to 45.
- Documentation: A press release detailing this announcement is filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the terms of the License and Collaboration Agreement between Miragen Therapeutics and Servier regarding MRG-110.
- Confirm the enrollment status and safety data from the Phase 1 trial of MRG-110.
- Review the company's cash runway and funding status, as this filing does not disclose current liquidity.
- Clarify the discrepancy between the requested company name (Viridian Therapeutics) and the filing registrant (Miragen Therapeutics).